NeuroPace, Inc. (NPCE) Stock Competitors & Peer Comparison
See (NPCE) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NPCE | $16.47 | +0.67% | 560.2M | -28.33 | -$0.58 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $94.12 | +0.94% | 163.8B | 18.05 | $5.21 | +2.60% |
| ISRG | $404.70 | +1.25% | 143.2B | 42.02 | $9.62 | N/A |
| SYK | $332.71 | +5.25% | 127.6B | 24.85 | $13.39 | +1.04% |
| MDT | $80.98 | +0.57% | 103.6B | 14.64 | $5.53 | +3.53% |
| BSX | $44.23 | +0.07% | 65.6B | 14.24 | $3.10 | N/A |
| EW | $90.78 | +1.18% | 52.3B | 33.64 | $2.70 | N/A |
| RMD | $200.29 | +0.85% | 29.1B | 18.60 | $10.77 | +1.20% |
| DXCM | $70.14 | +2.17% | 27.1B | 30.10 | $2.33 | N/A |
Stock Comparison
NPCE vs BSX-PA Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, NPCE is priced at $16.47, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, NPCE's ROE is -1.21%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, NPCE is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check BSX-PA's competition here
NPCE vs ABT Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, ABT has a market cap of 163.8B. Regarding current trading prices, NPCE is priced at $16.47, while ABT trades at $94.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas ABT's P/E ratio is 18.05. In terms of profitability, NPCE's ROE is -1.21%, compared to ABT's ROE of +0.12%. Regarding short-term risk, NPCE is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ABT's competition here
NPCE vs ISRG Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, ISRG has a market cap of 143.2B. Regarding current trading prices, NPCE is priced at $16.47, while ISRG trades at $404.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas ISRG's P/E ratio is 42.02. In terms of profitability, NPCE's ROE is -1.21%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, NPCE is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ISRG's competition here
NPCE vs SYK Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, SYK has a market cap of 127.6B. Regarding current trading prices, NPCE is priced at $16.47, while SYK trades at $332.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas SYK's P/E ratio is 24.85. In terms of profitability, NPCE's ROE is -1.21%, compared to SYK's ROE of +0.15%. Regarding short-term risk, NPCE is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check SYK's competition here
NPCE vs MDT Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, MDT has a market cap of 103.6B. Regarding current trading prices, NPCE is priced at $16.47, while MDT trades at $80.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas MDT's P/E ratio is 14.64. In terms of profitability, NPCE's ROE is -1.21%, compared to MDT's ROE of +0.10%. Regarding short-term risk, NPCE is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check MDT's competition here
NPCE vs BSX Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, BSX has a market cap of 65.6B. Regarding current trading prices, NPCE is priced at $16.47, while BSX trades at $44.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas BSX's P/E ratio is 14.24. In terms of profitability, NPCE's ROE is -1.21%, compared to BSX's ROE of +0.15%. Regarding short-term risk, NPCE is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check BSX's competition here
NPCE vs EW Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, EW has a market cap of 52.3B. Regarding current trading prices, NPCE is priced at $16.47, while EW trades at $90.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas EW's P/E ratio is 33.64. In terms of profitability, NPCE's ROE is -1.21%, compared to EW's ROE of +0.11%. Regarding short-term risk, NPCE is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check EW's competition here
NPCE vs RMD Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, RMD has a market cap of 29.1B. Regarding current trading prices, NPCE is priced at $16.47, while RMD trades at $200.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas RMD's P/E ratio is 18.60. In terms of profitability, NPCE's ROE is -1.21%, compared to RMD's ROE of +0.24%. Regarding short-term risk, NPCE is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check RMD's competition here
NPCE vs DXCM Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, DXCM has a market cap of 27.1B. Regarding current trading prices, NPCE is priced at $16.47, while DXCM trades at $70.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas DXCM's P/E ratio is 30.10. In terms of profitability, NPCE's ROE is -1.21%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, NPCE is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check DXCM's competition here
NPCE vs ZBH Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, ZBH has a market cap of 18B. Regarding current trading prices, NPCE is priced at $16.47, while ZBH trades at $93.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas ZBH's P/E ratio is 26.23. In terms of profitability, NPCE's ROE is -1.21%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, NPCE is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ZBH's competition here
NPCE vs ABMD Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, NPCE is priced at $16.47, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas ABMD's P/E ratio is 65.36. In terms of profitability, NPCE's ROE is -1.21%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, NPCE is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ABMD's competition here
NPCE vs ALGN Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, ALGN has a market cap of 12.8B. Regarding current trading prices, NPCE is priced at $16.47, while ALGN trades at $178.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas ALGN's P/E ratio is 16.27. In terms of profitability, NPCE's ROE is -1.21%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, NPCE is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ALGN's competition here
NPCE vs SNN Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, SNN has a market cap of 12.7B. Regarding current trading prices, NPCE is priced at $16.47, while SNN trades at $30.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas SNN's P/E ratio is 16.20. In terms of profitability, NPCE's ROE is -1.21%, compared to SNN's ROE of +0.12%. Regarding short-term risk, NPCE is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check SNN's competition here
NPCE vs SWAV Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, NPCE is priced at $16.47, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas SWAV's P/E ratio is 78.76. In terms of profitability, NPCE's ROE is -1.21%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, NPCE is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check SWAV's competition here
NPCE vs PEN Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, NPCE is priced at $16.47, while PEN trades at $316.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas PEN's P/E ratio is 82.70. In terms of profitability, NPCE's ROE is -1.21%, compared to PEN's ROE of +0.12%. Regarding short-term risk, NPCE is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check PEN's competition here
NPCE vs GMED Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, GMED has a market cap of 11.6B. Regarding current trading prices, NPCE is priced at $16.47, while GMED trades at $86.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas GMED's P/E ratio is 19.43. In terms of profitability, NPCE's ROE is -1.21%, compared to GMED's ROE of +0.13%. Regarding short-term risk, NPCE is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check GMED's competition here
NPCE vs PODD Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, PODD has a market cap of 11B. Regarding current trading prices, NPCE is priced at $16.47, while PODD trades at $158.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas PODD's P/E ratio is 29.41. In terms of profitability, NPCE's ROE is -1.21%, compared to PODD's ROE of +0.21%. Regarding short-term risk, NPCE is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check PODD's competition here
NPCE vs MASI Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, NPCE is priced at $16.47, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas MASI's P/E ratio is 44.43. In terms of profitability, NPCE's ROE is -1.21%, compared to MASI's ROE of +0.09%. Regarding short-term risk, NPCE is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check MASI's competition here
NPCE vs BRKR Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, BRKR has a market cap of 9.3B. Regarding current trading prices, NPCE is priced at $16.47, while BRKR trades at $60.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas BRKR's P/E ratio is 33.47. In terms of profitability, NPCE's ROE is -1.21%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, NPCE is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check BRKR's competition here
NPCE vs GKOS Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, GKOS has a market cap of 8.5B. Regarding current trading prices, NPCE is priced at $16.47, while GKOS trades at $144.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas GKOS's P/E ratio is -167.79. In terms of profitability, NPCE's ROE is -1.21%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, NPCE is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check GKOS's competition here
NPCE vs BIO Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, BIO has a market cap of 8.1B. Regarding current trading prices, NPCE is priced at $16.47, while BIO trades at $300.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas BIO's P/E ratio is 32.39. In terms of profitability, NPCE's ROE is -1.21%, compared to BIO's ROE of +0.02%. Regarding short-term risk, NPCE is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check BIO's competition here
NPCE vs BIO-B Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, BIO-B has a market cap of 8B. Regarding current trading prices, NPCE is priced at $16.47, while BIO-B trades at $317.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas BIO-B's P/E ratio is 94.17. In terms of profitability, NPCE's ROE is -1.21%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, NPCE is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check BIO-B's competition here
NPCE vs NARI Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, NPCE is priced at $16.47, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas NARI's P/E ratio is -59.24. In terms of profitability, NPCE's ROE is -1.21%, compared to NARI's ROE of -0.00%. Regarding short-term risk, NPCE is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check NARI's competition here
NPCE vs LIVN Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, LIVN has a market cap of 4.6B. Regarding current trading prices, NPCE is priced at $16.47, while LIVN trades at $83.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas LIVN's P/E ratio is 20.86. In terms of profitability, NPCE's ROE is -1.21%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, NPCE is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check LIVN's competition here
NPCE vs IRTC Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, IRTC has a market cap of 3.9B. Regarding current trading prices, NPCE is priced at $16.47, while IRTC trades at $118.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas IRTC's P/E ratio is -212.30. In terms of profitability, NPCE's ROE is -1.21%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, NPCE is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check IRTC's competition here
NPCE vs AXNX Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, NPCE is priced at $16.47, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas AXNX's P/E ratio is -709.80. In terms of profitability, NPCE's ROE is -1.21%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, NPCE is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check AXNX's competition here
NPCE vs ITGR Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, ITGR has a market cap of 3.2B. Regarding current trading prices, NPCE is priced at $16.47, while ITGR trades at $93.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas ITGR's P/E ratio is 14.90. In terms of profitability, NPCE's ROE is -1.21%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, NPCE is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ITGR's competition here
NPCE vs ESTA Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, ESTA has a market cap of 2.6B. Regarding current trading prices, NPCE is priced at $16.47, while ESTA trades at $88.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas ESTA's P/E ratio is -61.37. In terms of profitability, NPCE's ROE is -1.21%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, NPCE is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ESTA's competition here
NPCE vs AXGN Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, AXGN has a market cap of 2.4B. Regarding current trading prices, NPCE is priced at $16.47, while AXGN trades at $44.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas AXGN's P/E ratio is 118.24. In terms of profitability, NPCE's ROE is -1.21%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, NPCE is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check AXGN's competition here
NPCE vs TMDX Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, TMDX has a market cap of 2.4B. Regarding current trading prices, NPCE is priced at $16.47, while TMDX trades at $68.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas TMDX's P/E ratio is 27.93. In terms of profitability, NPCE's ROE is -1.21%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, NPCE is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check TMDX's competition here
NPCE vs BFLY Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, BFLY has a market cap of 2.3B. Regarding current trading prices, NPCE is priced at $16.47, while BFLY trades at $8.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas BFLY's P/E ratio is -36.87. In terms of profitability, NPCE's ROE is -1.21%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, NPCE is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check BFLY's competition here
NPCE vs NUVA Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, NPCE is priced at $16.47, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas NUVA's P/E ratio is 75.00. In terms of profitability, NPCE's ROE is -1.21%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, NPCE is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check NUVA's competition here
NPCE vs UFPT Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, UFPT has a market cap of 2B. Regarding current trading prices, NPCE is priced at $16.47, while UFPT trades at $259.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas UFPT's P/E ratio is 26.48. In terms of profitability, NPCE's ROE is -1.21%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, NPCE is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check UFPT's competition here
NPCE vs NVCR Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, NPCE is priced at $16.47, while NVCR trades at $15.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas NVCR's P/E ratio is -10.08. In terms of profitability, NPCE's ROE is -1.21%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, NPCE is more volatile compared to NVCR. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check NVCR's competition here
NPCE vs IART Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, IART has a market cap of 1.5B. Regarding current trading prices, NPCE is priced at $16.47, while IART trades at $18.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas IART's P/E ratio is 7.95. In terms of profitability, NPCE's ROE is -1.21%, compared to IART's ROE of -0.48%. Regarding short-term risk, NPCE is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check IART's competition here
NPCE vs ATEC Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, NPCE is priced at $16.47, while ATEC trades at $9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas ATEC's P/E ratio is -84.55. In terms of profitability, NPCE's ROE is -1.21%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, NPCE is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ATEC's competition here
NPCE vs AHCO Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, AHCO has a market cap of 1.4B. Regarding current trading prices, NPCE is priced at $16.47, while AHCO trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas AHCO's P/E ratio is 23.39. In terms of profitability, NPCE's ROE is -1.21%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, NPCE is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check AHCO's competition here
NPCE vs INSP Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, INSP has a market cap of 1.3B. Regarding current trading prices, NPCE is priced at $16.47, while INSP trades at $45.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas INSP's P/E ratio is 17.69. In terms of profitability, NPCE's ROE is -1.21%, compared to INSP's ROE of +0.18%. Regarding short-term risk, NPCE is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check INSP's competition here
NPCE vs HSKA Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, NPCE is priced at $16.47, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas HSKA's P/E ratio is -62.49. In terms of profitability, NPCE's ROE is -1.21%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, NPCE is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check HSKA's competition here
NPCE vs ENOV Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, ENOV has a market cap of 1.3B. Regarding current trading prices, NPCE is priced at $16.47, while ENOV trades at $22.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas ENOV's P/E ratio is 6.71. In terms of profitability, NPCE's ROE is -1.21%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, NPCE is more volatile compared to ENOV. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ENOV's competition here
NPCE vs PRCT Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, PRCT has a market cap of 1.3B. Regarding current trading prices, NPCE is priced at $16.47, while PRCT trades at $22.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas PRCT's P/E ratio is -12.40. In terms of profitability, NPCE's ROE is -1.21%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, NPCE is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check PRCT's competition here
NPCE vs IRMD Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, NPCE is priced at $16.47, while IRMD trades at $93.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas IRMD's P/E ratio is 47.22. In terms of profitability, NPCE's ROE is -1.21%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, NPCE is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check IRMD's competition here
NPCE vs AVNS Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, NPCE is priced at $16.47, while AVNS trades at $24.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas AVNS's P/E ratio is 27.71. In terms of profitability, NPCE's ROE is -1.21%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, NPCE is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check AVNS's competition here
NPCE vs LMRI Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, LMRI has a market cap of 1.2B. Regarding current trading prices, NPCE is priced at $16.47, while LMRI trades at $12.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas LMRI's P/E ratio is -23.54. In terms of profitability, NPCE's ROE is -1.21%, compared to LMRI's ROE of -0.14%. Regarding short-term risk, NPCE is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check LMRI's competition here
NPCE vs AORT Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, NPCE is priced at $16.47, while AORT trades at $23.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas AORT's P/E ratio is 36.29. In terms of profitability, NPCE's ROE is -1.21%, compared to AORT's ROE of +0.03%. Regarding short-term risk, NPCE is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check AORT's competition here
NPCE vs SILK Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, NPCE is priced at $16.47, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas SILK's P/E ratio is -18.96. In terms of profitability, NPCE's ROE is -1.21%, compared to SILK's ROE of -0.35%. Regarding short-term risk, NPCE is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check SILK's competition here
NPCE vs TNDM Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, NPCE is priced at $16.47, while TNDM trades at $16.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas TNDM's P/E ratio is -14.76. In terms of profitability, NPCE's ROE is -1.21%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, NPCE is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check TNDM's competition here
NPCE vs FNA Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, NPCE is priced at $16.47, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas FNA's P/E ratio is -19.83. In terms of profitability, NPCE's ROE is -1.21%, compared to FNA's ROE of -0.35%. Regarding short-term risk, NPCE is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check FNA's competition here
NPCE vs CNMD Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, NPCE is priced at $16.47, while CNMD trades at $35.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas CNMD's P/E ratio is 7.90. In terms of profitability, NPCE's ROE is -1.21%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, NPCE is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check CNMD's competition here
NPCE vs CSII Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, NPCE is priced at $16.47, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas CSII's P/E ratio is -20.83. In terms of profitability, NPCE's ROE is -1.21%, compared to CSII's ROE of -0.14%. Regarding short-term risk, NPCE is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check CSII's competition here
NPCE vs INMD Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, INMD has a market cap of 840.9M. Regarding current trading prices, NPCE is priced at $16.47, while INMD trades at $14.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas INMD's P/E ratio is 9.38. In terms of profitability, NPCE's ROE is -1.21%, compared to INMD's ROE of +0.13%. Regarding short-term risk, NPCE is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check INMD's competition here
NPCE vs SIBN Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, SIBN has a market cap of 768.6M. Regarding current trading prices, NPCE is priced at $16.47, while SIBN trades at $17.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas SIBN's P/E ratio is -44.44. In terms of profitability, NPCE's ROE is -1.21%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, NPCE is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check SIBN's competition here
NPCE vs CBLL Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, CBLL has a market cap of 758.1M. Regarding current trading prices, NPCE is priced at $16.47, while CBLL trades at $19.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas CBLL's P/E ratio is -12.26. In terms of profitability, NPCE's ROE is -1.21%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, NPCE is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check CBLL's competition here
NPCE vs CRY Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, NPCE is priced at $16.47, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas CRY's P/E ratio is 425.71. In terms of profitability, NPCE's ROE is -1.21%, compared to CRY's ROE of +0.03%. Regarding short-term risk, NPCE is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check CRY's competition here
NPCE vs TCMD Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, TCMD has a market cap of 683M. Regarding current trading prices, NPCE is priced at $16.47, while TCMD trades at $30.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas TCMD's P/E ratio is 34.41. In terms of profitability, NPCE's ROE is -1.21%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, NPCE is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check TCMD's competition here
NPCE vs SSII Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, SSII has a market cap of 668.4M. Regarding current trading prices, NPCE is priced at $16.47, while SSII trades at $3.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas SSII's P/E ratio is -65.15. In terms of profitability, NPCE's ROE is -1.21%, compared to SSII's ROE of -0.23%. Regarding short-term risk, NPCE is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check SSII's competition here
NPCE vs BVS Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, BVS has a market cap of 660.5M. Regarding current trading prices, NPCE is priced at $16.47, while BVS trades at $9.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas BVS's P/E ratio is 13.00. In terms of profitability, NPCE's ROE is -1.21%, compared to BVS's ROE of +0.16%. Regarding short-term risk, NPCE is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check BVS's competition here
NPCE vs SRDX Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, NPCE is priced at $16.47, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas SRDX's P/E ratio is -34.66. In terms of profitability, NPCE's ROE is -1.21%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, NPCE is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check SRDX's competition here
NPCE vs CERS Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, CERS has a market cap of 585.1M. Regarding current trading prices, NPCE is priced at $16.47, while CERS trades at $2.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas CERS's P/E ratio is -58.28. In terms of profitability, NPCE's ROE is -1.21%, compared to CERS's ROE of -0.15%. Regarding short-term risk, NPCE is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check CERS's competition here
NPCE vs APEN Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, NPCE is priced at $16.47, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas APEN's P/E ratio is -9.43. In terms of profitability, NPCE's ROE is -1.21%, compared to APEN's ROE of -0.85%. Regarding short-term risk, NPCE is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check APEN's competition here
NPCE vs CTKB Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, CTKB has a market cap of 578.6M. Regarding current trading prices, NPCE is priced at $16.47, while CTKB trades at $4.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas CTKB's P/E ratio is -34.46. In terms of profitability, NPCE's ROE is -1.21%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, NPCE is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check CTKB's competition here
NPCE vs BWAY Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, BWAY has a market cap of 567.9M. Regarding current trading prices, NPCE is priced at $16.47, while BWAY trades at $14.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas BWAY's P/E ratio is 36.78. In terms of profitability, NPCE's ROE is -1.21%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, NPCE is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check BWAY's competition here
NPCE vs CLPT Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, CLPT has a market cap of 554.2M. Regarding current trading prices, NPCE is priced at $16.47, while CLPT trades at $18.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas CLPT's P/E ratio is -18.30. In terms of profitability, NPCE's ROE is -1.21%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, NPCE is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check CLPT's competition here
NPCE vs ZIMV Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, NPCE is priced at $16.47, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, NPCE's ROE is -1.21%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, NPCE is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ZIMV's competition here
NPCE vs KIDS Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, KIDS has a market cap of 521.4M. Regarding current trading prices, NPCE is priced at $16.47, while KIDS trades at $20.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas KIDS's P/E ratio is -19.71. In terms of profitability, NPCE's ROE is -1.21%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, NPCE is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check KIDS's competition here
NPCE vs PACB Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, PACB has a market cap of 512.5M. Regarding current trading prices, NPCE is priced at $16.47, while PACB trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas PACB's P/E ratio is -3.37. In terms of profitability, NPCE's ROE is -1.21%, compared to PACB's ROE of -4.88%. Regarding short-term risk, NPCE is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check PACB's competition here
NPCE vs DCTH Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, DCTH has a market cap of 446.7M. Regarding current trading prices, NPCE is priced at $16.47, while DCTH trades at $12.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas DCTH's P/E ratio is 1294.00. In terms of profitability, NPCE's ROE is -1.21%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, NPCE is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check DCTH's competition here
NPCE vs VREX Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, VREX has a market cap of 432.4M. Regarding current trading prices, NPCE is priced at $16.47, while VREX trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas VREX's P/E ratio is 10.81. In terms of profitability, NPCE's ROE is -1.21%, compared to VREX's ROE of -0.18%. Regarding short-term risk, NPCE is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check VREX's competition here
NPCE vs OFIX Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, OFIX has a market cap of 395.3M. Regarding current trading prices, NPCE is priced at $16.47, while OFIX trades at $9.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas OFIX's P/E ratio is -39.84. In terms of profitability, NPCE's ROE is -1.21%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, NPCE is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check OFIX's competition here
NPCE vs AVR Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, AVR has a market cap of 356.5M. Regarding current trading prices, NPCE is priced at $16.47, while AVR trades at $9.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas AVR's P/E ratio is -4.35. In terms of profitability, NPCE's ROE is -1.21%, compared to AVR's ROE of -1.24%. Regarding short-term risk, NPCE is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check AVR's competition here
NPCE vs ELMD Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, ELMD has a market cap of 341.3M. Regarding current trading prices, NPCE is priced at $16.47, while ELMD trades at $41.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas ELMD's P/E ratio is 35.23. In terms of profitability, NPCE's ROE is -1.21%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, NPCE is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check ELMD's competition here
NPCE vs SMLR Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, NPCE is priced at $16.47, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas SMLR's P/E ratio is 3.92. In terms of profitability, NPCE's ROE is -1.21%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, NPCE is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check SMLR's competition here
NPCE vs SGHT Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, SGHT has a market cap of 309.6M. Regarding current trading prices, NPCE is priced at $16.47, while SGHT trades at $5.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas SGHT's P/E ratio is -9.03. In terms of profitability, NPCE's ROE is -1.21%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, NPCE is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check SGHT's competition here
NPCE vs TMCI Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, TMCI has a market cap of 289.3M. Regarding current trading prices, NPCE is priced at $16.47, while TMCI trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas TMCI's P/E ratio is -4.74. In terms of profitability, NPCE's ROE is -1.21%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, NPCE is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check TMCI's competition here
NPCE vs PMI Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, PMI has a market cap of 250.7M. Regarding current trading prices, NPCE is priced at $16.47, while PMI trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas PMI's P/E ratio is -0.13. In terms of profitability, NPCE's ROE is -1.21%, compared to PMI's ROE of +4.99%. Regarding short-term risk, NPCE is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check PMI's competition here
NPCE vs MGRM Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, NPCE is priced at $16.47, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas MGRM's P/E ratio is -11.11. In terms of profitability, NPCE's ROE is -1.21%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, NPCE is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check MGRM's competition here
NPCE vs SENS Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, SENS has a market cap of 239.1M. Regarding current trading prices, NPCE is priced at $16.47, while SENS trades at $5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas SENS's P/E ratio is -2.86. In terms of profitability, NPCE's ROE is -1.21%, compared to SENS's ROE of -1.30%. Regarding short-term risk, NPCE is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check SENS's competition here
NPCE vs CATX Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, CATX has a market cap of 231.8M. Regarding current trading prices, NPCE is priced at $16.47, while CATX trades at $3.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas CATX's P/E ratio is -2.13. In terms of profitability, NPCE's ROE is -1.21%, compared to CATX's ROE of -0.42%. Regarding short-term risk, NPCE is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check CATX's competition here
NPCE vs NVRO Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, NPCE is priced at $16.47, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas NVRO's P/E ratio is -1.91. In terms of profitability, NPCE's ROE is -1.21%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, NPCE is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check NVRO's competition here
NPCE vs RXST Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, RXST has a market cap of 221.9M. Regarding current trading prices, NPCE is priced at $16.47, while RXST trades at $5.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas RXST's P/E ratio is -7.44. In terms of profitability, NPCE's ROE is -1.21%, compared to RXST's ROE of -0.17%. Regarding short-term risk, NPCE is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check RXST's competition here
NPCE vs EYES Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, NPCE is priced at $16.47, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas EYES's P/E ratio is N/A. In terms of profitability, NPCE's ROE is -1.21%, compared to EYES's ROE of -2.64%. Regarding short-term risk, NPCE is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check EYES's competition here
NPCE vs QTRX Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, QTRX has a market cap of 203.5M. Regarding current trading prices, NPCE is priced at $16.47, while QTRX trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas QTRX's P/E ratio is -2.70. In terms of profitability, NPCE's ROE is -1.21%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, NPCE is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check QTRX's competition here
NPCE vs ANIK Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, ANIK has a market cap of 200.9M. Regarding current trading prices, NPCE is priced at $16.47, while ANIK trades at $15.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas ANIK's P/E ratio is 30.82. In terms of profitability, NPCE's ROE is -1.21%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, NPCE is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ANIK's competition here
NPCE vs PROF Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, PROF has a market cap of 196.7M. Regarding current trading prices, NPCE is priced at $16.47, while PROF trades at $6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas PROF's P/E ratio is -5.24. In terms of profitability, NPCE's ROE is -1.21%, compared to PROF's ROE of -0.70%. Regarding short-term risk, NPCE is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check PROF's competition here
NPCE vs FOCL Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, FOCL has a market cap of 191.2M. Regarding current trading prices, NPCE is priced at $16.47, while FOCL trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas FOCL's P/E ratio is -10.31. In terms of profitability, NPCE's ROE is -1.21%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, NPCE is less volatile compared to FOCL. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check FOCL's competition here
NPCE vs BSGM Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, NPCE is priced at $16.47, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas BSGM's P/E ratio is -5.81. In terms of profitability, NPCE's ROE is -1.21%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, NPCE is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check BSGM's competition here
NPCE vs INGN Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, INGN has a market cap of 187.9M. Regarding current trading prices, NPCE is priced at $16.47, while INGN trades at $6.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas INGN's P/E ratio is -7.63. In terms of profitability, NPCE's ROE is -1.21%, compared to INGN's ROE of -0.13%. Regarding short-term risk, NPCE is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check INGN's competition here
NPCE vs TLSI Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, TLSI has a market cap of 179.3M. Regarding current trading prices, NPCE is priced at $16.47, while TLSI trades at $4.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas TLSI's P/E ratio is -2.82. In terms of profitability, NPCE's ROE is -1.21%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, NPCE is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check TLSI's competition here
NPCE vs MDGS Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, NPCE is priced at $16.47, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas MDGS's P/E ratio is -0.27. In terms of profitability, NPCE's ROE is -1.21%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, NPCE is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check MDGS's competition here
NPCE vs QIPT Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, NPCE is priced at $16.47, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas QIPT's P/E ratio is -15.87. In terms of profitability, NPCE's ROE is -1.21%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, NPCE is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check QIPT's competition here
NPCE vs CVRX Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, CVRX has a market cap of 155.5M. Regarding current trading prices, NPCE is priced at $16.47, while CVRX trades at $5.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas CVRX's P/E ratio is -2.90. In terms of profitability, NPCE's ROE is -1.21%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, NPCE is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check CVRX's competition here
NPCE vs QTI Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, QTI has a market cap of 110.4M. Regarding current trading prices, NPCE is priced at $16.47, while QTI trades at $4.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas QTI's P/E ratio is -5.99. In terms of profitability, NPCE's ROE is -1.21%, compared to QTI's ROE of -63.31%. Regarding short-term risk, NPCE is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check QTI's competition here
NPCE vs LUCD Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, LUCD has a market cap of 108.4M. Regarding current trading prices, NPCE is priced at $16.47, while LUCD trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas LUCD's P/E ratio is -2.86. In terms of profitability, NPCE's ROE is -1.21%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, NPCE is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check LUCD's competition here
NPCE vs ICAD Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, NPCE is priced at $16.47, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas ICAD's P/E ratio is -20.37. In terms of profitability, NPCE's ROE is -1.21%, compared to ICAD's ROE of -0.06%. Regarding short-term risk, NPCE is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ICAD's competition here
NPCE vs HSDT Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, HSDT has a market cap of 101M. Regarding current trading prices, NPCE is priced at $16.47, while HSDT trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas HSDT's P/E ratio is -0.02. In terms of profitability, NPCE's ROE is -1.21%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, NPCE is less volatile compared to HSDT. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check HSDT's competition here
NPCE vs OWLT Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, OWLT has a market cap of 99.3M. Regarding current trading prices, NPCE is priced at $16.47, while OWLT trades at $5.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas OWLT's P/E ratio is -39.21. In terms of profitability, NPCE's ROE is -1.21%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, NPCE is more volatile compared to OWLT. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check OWLT's competition here
NPCE vs RCEL Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, RCEL has a market cap of 98.6M. Regarding current trading prices, NPCE is priced at $16.47, while RCEL trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas RCEL's P/E ratio is -2.53. In terms of profitability, NPCE's ROE is -1.21%, compared to RCEL's ROE of +3.05%. Regarding short-term risk, NPCE is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check RCEL's competition here
NPCE vs HJLI Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, NPCE is priced at $16.47, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas HJLI's P/E ratio is N/A. In terms of profitability, NPCE's ROE is -1.21%, compared to HJLI's ROE of -0.66%. Regarding short-term risk, NPCE is more volatile compared to HJLI. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check HJLI's competition here
NPCE vs ASXC Comparison June 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 560.2M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, NPCE is priced at $16.47, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -28.33, whereas ASXC's P/E ratio is -1.12. In terms of profitability, NPCE's ROE is -1.21%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, NPCE is more volatile compared to ASXC. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ASXC's competition here